140 related articles for article (PubMed ID: 36178966)
21. 3D directional gradient L
Shi Y; Wang Y; Meng F; Zhou J; Wen B; Zhang X; Liu Y; Li L; Li J; Cao X; Kang F; Zhu S
Comput Biol Med; 2023 Jul; 161():107010. PubMed ID: 37235943
[TBL] [Abstract][Full Text] [Related]
22. Exploiting sparsity and low-rank structure for the recovery of multi-slice breast MRIs with reduced sampling error.
Yin XX; Ng BW; Ramamohanarao K; Baghai-Wadji A; Abbott D
Med Biol Eng Comput; 2012 Sep; 50(9):991-1000. PubMed ID: 22644257
[TBL] [Abstract][Full Text] [Related]
23. MIMIC: an optimization method to identify cell type-specific marker panel for cell sorting.
Zou M; Duren Z; Yuan Q; Li H; Hutchins AP; Wong WH; Wang Y
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180954
[TBL] [Abstract][Full Text] [Related]
24. Selection of optimal quantile protein biomarkers based on cell-level immunohistochemistry data.
Yi M; Zhan T; Peck AR; Hooke JA; Kovatich AJ; Shriver CD; Hu H; Sun Y; Rui H; Chervoneva I
BMC Bioinformatics; 2023 Jul; 24(1):298. PubMed ID: 37481512
[TBL] [Abstract][Full Text] [Related]
25. A new projection correction based voting strategy for breast calcification artifact reduction.
Tang H; Wang J; Sun L; Wang S; Xiang J; Xi Y; Chen Y; Jiang Y
Phys Med Biol; 2023 Sep; 68(18):. PubMed ID: 37582378
[No Abstract] [Full Text] [Related]
26. Improved breast ultrasound tumor classification using dual-input CNN with GAP-guided attention loss.
Zou X; Zhai J; Qian S; Li A; Tian F; Cao X; Wang R
Math Biosci Eng; 2023 Jul; 20(8):15244-15264. PubMed ID: 37679179
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
28. Mixture classification model based on clinical markers for breast cancer prognosis.
Zeng T; Liu J
Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization of breast cancer cell lines through multiple omic approaches.
Smith SE; Mellor P; Ward AK; Kendall S; McDonald M; Vizeacoumar FS; Vizeacoumar FJ; Napper S; Anderson DH
Breast Cancer Res; 2017 Jun; 19(1):65. PubMed ID: 28583138
[TBL] [Abstract][Full Text] [Related]
30. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
[TBL] [Abstract][Full Text] [Related]
31. A 40-Marker Panel for High Dimensional Characterization of Cancer Immune Microenvironments by Imaging Mass Cytometry.
Ijsselsteijn ME; van der Breggen R; Farina Sarasqueta A; Koning F; de Miranda NFCC
Front Immunol; 2019; 10():2534. PubMed ID: 31736961
[TBL] [Abstract][Full Text] [Related]
32. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays.
Stopsack KH; Tyekucheva S; Wang M; Gerke TA; Vaselkiv JB; Penney KL; Kantoff PW; Finn SP; Fiorentino M; Loda M; Lotan TL; Parmigiani G; Mucci LA
Elife; 2021 Dec; 10():. PubMed ID: 34939926
[TBL] [Abstract][Full Text] [Related]
33. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
[TBL] [Abstract][Full Text] [Related]
35. Comparison of ring artifact removal methods using flat panel detector based CT images.
Anas EM; Kim JG; Lee SY; Hasan K
Biomed Eng Online; 2011 Aug; 10():72. PubMed ID: 21846411
[TBL] [Abstract][Full Text] [Related]
36. Expanding the Comprehension of the Tumor Microenvironment using Mass Spectrometry Imaging of Formalin-Fixed and Paraffin-Embedded Tissue Samples.
Campos Clemente L; Shi O; Rojas F; Parra ER
J Vis Exp; 2022 Jun; (184):. PubMed ID: 35848832
[TBL] [Abstract][Full Text] [Related]
37. Advances in quantitative immunohistochemistry and their contribution to breast cancer.
Yaghoobi V; Martinez-Morilla S; Liu Y; Charette L; Rimm DL; Harigopal M
Expert Rev Mol Diagn; 2020 May; 20(5):509-522. PubMed ID: 32178550
[No Abstract] [Full Text] [Related]
38. CyTOFmerge: integrating mass cytometry data across multiple panels.
Abdelaal T; Höllt T; van Unen V; Lelieveldt BPF; Koning F; Reinders MJT; Mahfouz A
Bioinformatics; 2019 Oct; 35(20):4063-4071. PubMed ID: 30874801
[TBL] [Abstract][Full Text] [Related]
39. Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk.
O'Leary E; Iacoboni D; Holle J; Michalski ST; Esplin ED; Yang S; Ouyang K
Ann Surg Oncol; 2017 Oct; 24(10):3060-3066. PubMed ID: 28766213
[TBL] [Abstract][Full Text] [Related]
40. Feasibility study of a point-of-care positron emission tomography system with interactive imaging capability.
Jiang J; Li K; Komarov S; O'Sullivan JA; Tai YC
Med Phys; 2019 Apr; 46(4):1798-1813. PubMed ID: 30667069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
